Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
17 reports, 5 independent
Updated Oct 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 17
- Developments
- 7
- Repetition
- 65%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Viking and Novo Nordisk develop amylin agonists; S&P Global forecasts Viking's cash burn.1 source
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.Sub-event
Successful clinical data leads to market share gains among the three major weight loss drug companies.1 source
Companies are developing dual GLP-1/GIP agonists for weight loss.1 source
Viking Therapeutics is seeking market share in the competitive weight loss drug market dominated by Eli Lilly and Novo Nordisk.1 source
Viking, Lilly, and Novo Nordisk are developing weight loss drugs, with Lilly planning FDA approval.1 source
- Viking's drug is similar to Eli Lilly's Zepbound as the weight loss drug market competition heats up.
Keep exploring
Part of
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Also in this story
- Pfizer acquired Metsera after a bidding war with Novo Nordisk.
- Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.
- Institutional investor Stanley Druckenmiller's firm must file Form 13F with the SEC regarding its new position in Viking Therapeutics, amidst market competition among weight loss drug companies.
- Eli Lilly and Novo Nordisk faced legal actions and partnership terminations regarding compliance and customer deception.
The entities involved
-
Viking Therapeutics
company in San Diego, United States
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Hanmi Pharmaceutical won approval for its homegrown GLP-1 obesity drug, while Eli Lilly expands its market presence.
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.
- Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.
Coverage
Newest first; wire copies grouped- fool.com
- aol.com
- yahoo.com
- yahoo.com
- fool.com
- yahoo.com
- yahoo.com
- Motley FoolThe 3 Things That Matter for Viking Therapeutics Now Viking Therapeutics has key weight loss drugs in phase 2 and phase 3 trials. The race is on to bring an oral formulation weight loss medication to
- Insider MonkeyViking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on o
- Unknown outlet
- Unknown outlet
- Unknown outlet
- Unknown outlet